CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate

* CStone to acquire exclusive rights for development and commercialization outsideSouth Korea for LCB71, an ROR1 antibody drug conjugate * Agreement adds to CStone's pipeline a potential first-in-class/best-in-class drug candidate with monotherapy and combination applications for a range of c...

2020-10-29 07:15 1515